Mark W. Douglas, Enoch S.E. Tay, Dao Sen Wang, Adrian T.L. Ong, Caroline Wilson, Amy Phu, Jen Kok, Dominic E. Dwyer, Rowena A. Bull, Andrew R. Lloyd, Tanya L. Applegate, Gregory J. Dore, Anita Y. Howe, Richard Harrigan, Jacob George – 6 April 2020 – Direct acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment, but drug resistance could undermine proposed global elimination targets. Real‐world studies are needed to inform the impact of widespread DAA treatment on antiviral resistance in the community.

Priscila Santiago, Cynthia Levy – 4 April 2020

Alessandro Mantovani, Giorgia Beatrice, Andrea Dalbeni – 4 April 2020 – At present, there is scarce information regarding the global prevalence of chronic liver disease in individuals with coronavirus disease 2019 (COVID‐19) disease, which is becoming a global pandemic. The aim of this study was to assess the overall prevalence of chronic liver disease among patients with COVID‐19 disease by meta‐analysing data in observational studies and to investigate the relationship between liver damage and COVID‐19 disease.

Mauro Viganò, Marco Carbone – 4 April 2020

Ashish Kumar, Praveen Sharma, Anil Arora – 4 April 2020

John Y.L. Chiang, Jessica M. Ferrell – 4 April 2020

Mauro Viganò, Marco Carbone – 4 April 2020

Isabel M. A. Brüggenwirth, Robert J. Porte, Paulo N. Martins – 4 April 2020 – Bile secretion and composition reflects the functional status of hepatocytes and cholangiocytes. Bile composition can have a role in the assessment of donor grafts before implantation in the recipient. In addition, changes in bile composition after liver transplantation can serve as a diagnostic and prognostic tool to predict posttransplant complications, such as primary nonfunction, acute cellular rejection, or nonanastomotic biliary strictures.

James M. Paik, Pegah Golabi, Rakesh Biswas, Saleh Alqahtani, Chapy Venkatesan, Zobair M. Younossi – 4 April 2020 – In the United States, chronic viral hepatitis B and C (CHB and CHC), nonalcoholic fatty liver disease (NAFLD), and alcohol‐related liver disease (ALD) are the main causes of liver deaths attributable to hepatocellular carcinoma (HCC) and cirrhosis. Our aim was to assess the changes in the rates of mortality and years of potential life lost (YLL) for HCC and cirrhosis due to different liver diseases.

Saul J. Karpen – 4 April 2020